Court rules Remicade patent is invalid
The U.S. District Court in Massachusetts Federal Court has ruled a patent for Remicade, a top-selling rheumatoid arthritis drug sold by Johnson& Johnson subsidiary Janssen Biotech, is invalid.
The court sided with the request for a summary judgement in the patent infringement dispute filed by Celltrion Healthcare Co. Ltd and Pfizer-owned Hospira Healthcare Corp., which want to sell a biosimilar version of the product.
Johnson& Johnson (NYSE; JNJ) issued a statement following the ruling in which …
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Arthritis | Biotechnology | Health | Health Management | Legislation | Pfizer | Pharmaceuticals | Remicade | Rheumatoid Arthritis | Rheumatology